Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 Trial

Results from the randomized SWOG S1406 trial (NCT02164916) indicated that simultaneous use of an EGFR plus a BRAF inhibitor combined with irinotecan was found to be effective in BRAF V600E–mutated colorectal cancer (CRC).¹

The first cooperative group study in CRC to prospectively assess a molecular biomarker addressing a small patient subset, SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E­–mutated metastatic CRC who had been previously treated with 1 or 2 regimens.

The study, published in the Journal of Clinical Oncology, was led by Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center.² In an interview with CancerNetwork®, Kopetz discussed the results of the study and what they may offer patients with BRAF V600E­–mutated metastatic CRC.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences channels.

References:

1. Kopetz S, Guthrie KA, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).J Clin Oncol. Published online December 23, 2020. doi: 10.1200/JCO.20.01994

2. Triple Chemo Combo Improves CRC Outcomes. News release. Published December 23, 2020. Accessed January 11, 2021. https://www.swog.org/news-events/news/2020/12/23/triple-chemo-combo-improves-crc-outcomes